{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:58:46Z","timestamp":1776419926298,"version":"3.51.2"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,30]],"date-time":"2006-01-30T00:00:00Z","timestamp":1138579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>In 2002, the Centers for Disease Control and Prevention established the Vaccine Analytic Unit (VAU) in collaboration with the Department of Defense (DoD). The focus of this report is to describe the process by which the VAU's anthrax vaccine safety research plan was developed following a comprehensive review of these topics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Public health literature, surveillance data, and clinical sources were reviewed to create a list of adverse events hypothesized to be potentially related to anthrax vaccine adsorbed (AVA). From this list, a consensus process was used to select 11 important research topics. Adverse event background papers were written for each of these topics, addressing predetermined criteria. These were independently reviewed and ranked by a National Vaccine Advisory Committee (NVAC) workgroup. The adverse events included in the final priority list will be the subject of observational or other post marketing surveillance studies using the Defense Medical Surveillance System (DMSS) database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A review of various information sources identified over 100 potential adverse events. The review process recommended 11 topics as potentially warranting further study. The NVAC workgroup identified the following adverse event topics for study: arthritis, optic neuritis, and Stevens\u2013Johnson syndrome\/Toxic epidermal necrolysis. Two additional topics (systemic lupus erythematosus (SLE) and multiple, near\u2010concurrent military vaccinations) were added in response to emerging public health and military concerns.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The experience described, while specific for establishing the VAU's research agenda for the safety of the current anthrax vaccine, may be useful and adapted for research planning in other areas of public health research. Copyright \u00a9 2006 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1213","type":"journal-article","created":{"date-parts":[[2006,1,30]],"date-time":"2006-01-30T11:20:41Z","timestamp":1138620041000},"page":"46-54","source":"Crossref","is-referenced-by-count":18,"title":["Development of the Vaccine Analytic Unit's research agenda for investigating potential adverse events associated with anthrax vaccine adsorbed"],"prefix":"10.1002","volume":"16","author":[{"given":"Daniel C.","family":"Payne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura H.","family":"Franzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Stehr\u2010Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,12,20]]},"reference":[{"key":"e_1_2_1_2_2","volume-title":"The Anthrax Vaccine: Is it Safe? Does it Work?","author":"Institute of Medicine","year":"2002"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00723-5"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.06.026"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jom.0000141664.90587.47"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2004.07.965"},{"key":"e_1_2_1_7_2","volume-title":"An assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program","author":"Institute of Medicine","year":"2003"},{"key":"e_1_2_1_8_2","first-page":"49","article-title":"Use of anthrax vaccine in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","author":"CDC","year":"2000","journal-title":"Mor Mortal Wkly Rep"},{"key":"e_1_2_1_9_2","unstructured":"Anthrax Vaccine Adsorbed (BIOTHRAX\u2122) Package Insert.2002.Manufactured by Bioport Corporation Lansing Michigan US Lic No. 1260."},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.92.12.1900"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.712"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.936"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00387-5"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00058-0"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.7205\/MILMED.169.10.833"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jom.0000058345.05741.6b"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00435-3"},{"issue":"5","key":"e_1_2_1_18_2","first-page":"9","article-title":"Acute side effects of anthrax vaccine in ROTC cadets participating in advanced camp, Fort Lewis, 2000","volume":"7","author":"Gunzenhauser JD","year":"2001","journal-title":"Med Surv Monthly Rep"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/milmed\/167.3.205","article-title":"Ambulatory medical visits among anthrax vaccinated and unvaccinated personnel after return from southwest Asia","volume":"167","author":"Rehme PA","year":"2002","journal-title":"Mil Med"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.12.1556"},{"key":"e_1_2_1_21_2","volume-title":"Pharmacoepidemiology","author":"Chen R","year":"1994"},{"key":"e_1_2_1_22_2","volume-title":"Group techniques for program planning: A guide to nominal group and Delphi processes","author":"Delbecq A","year":"1975"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/003591576505800503"},{"key":"e_1_2_1_24_2","unstructured":"WinkenwerderWJr M.D. Assistant Secretary of Defense.Memorandum: Learning from Adverse Events after Vaccination. November 26 2003.http:\/\/www.smallpox.army.mil\/media\/pdf\/learjingAdEvents.pdf"},{"key":"e_1_2_1_25_2","unstructured":"Armed Forces Epidemiological Board.Recommendation 2004\u201004: Multiple concurrent immunizations and safety concerns. Falls Church VA: 16 April2004.www.vaccines.mil\/documents\/477AFEB2004.pdf"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.613"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1213","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T04:52:26Z","timestamp":1700023946000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,20]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1002\/pds.1213"],"URL":"https:\/\/doi.org\/10.1002\/pds.1213","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12,20]]}}}